Intellia Therapeutics (NTLA) Accounts Payables (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Accounts Payables of $18.8 million for Q1 2026, up 52.05% year-over-year from $12.4 million in Q1 2025, and down 7.17% quarter-over-quarter from $20.3 million in Q4 2025.
Intellia Therapeutics (NTLA) Accounts Payables (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Accounts Payables for 12 consecutive years, with $18.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 52.05% year-over-year to $18.8 million; the TTM figure through Mar 2026 stood at $18.8 million (up 52.05% YoY), while the FY2025 annual figure was $20.3 million, up 38.82% from the prior year.
- Accounts Payables declined to $18.8 million in Q1 2026 per NTLA's latest filing, from $20.3 million in the prior quarter.
- Across five years, Accounts Payables topped out at $20.3 million in Q4 2025 and bottomed at $3.6 million in Q3 2023.
- Historically, Accounts Payables has averaged $11.3 million across 5 years, with a median of $11.6 million in 2023.
- Annual changes were most pronounced in 2024 — Accounts Payables jumped 269.97% — and 2025, when it slumped 47.91%.
- Intellia Therapeutics' Accounts Payables stood at $5.2 million in 2022, then surged by 44.59% to $7.5 million in 2023, then jumped by 95.77% to $14.6 million in 2024, then soared by 38.82% to $20.3 million in 2025, then decreased by 7.17% to $18.8 million in 2026.
- Business Quant data shows NTLA's Accounts Payables at $18.8 million in Q1 2026, $20.3 million in Q4 2025, and $13.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 11.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.71 Mn |
| Mar 31, 2026 | 18.80 Mn |
| Dec 31, 2025 | 20.25 Mn |
| Sep 30, 2025 | 13.26 Mn |
| Jun 30, 2025 | 9.80 Mn |
| Mar 31, 2025 | 12.36 Mn |
| Dec 31, 2024 | 14.59 Mn |
| Sep 30, 2024 | 13.15 Mn |
| Jun 30, 2024 | 18.82 Mn |
| Mar 31, 2024 | 13.69 Mn |
| Dec 31, 2023 | 7.45 Mn |
| Sep 30, 2023 | 3.55 Mn |
| Jun 30, 2023 | 11.63 Mn |
| Mar 31, 2023 | 6.89 Mn |
| Dec 31, 2022 | 5.15 Mn |
| Sep 30, 2022 | 4.38 Mn |
| Jun 30, 2022 | 7.52 Mn |
| Mar 31, 2022 | 10.14 Mn |
| Dec 31, 2021 | 9.65 Mn |
| Sep 30, 2021 | 7.47 Mn |